Literature DB >> 7452889

Familial hypocomplementemic hemolytic uremic syndrome with HLA-A3,B7 haplotype.

L Carreras, R Romero, C Requesens, A J Oliver, M Carrera, M Clavo, J Alsina.   

Abstract

We describe a familial, relapsing type of hemolytic uremic syndrome (HUS) that has a possible genetic origin. Three members of a family, aged between 15 months and 34 years, evidenced HUS. Histological examination disclosed thrombotic microangiopathy. Recurrences, persistent hypocomplementemia, and the HLA haplotype A3,B7 were a common factor. We studied 17 members of this family and found a low C3 level from activation of the alternative pathway in the haplotype A3,B7 carriers. These three patients with HUS probably had a congenital and hereditary condition in which immunologic factors played a role in its pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7452889

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  17 in total

Review 1.  Glomerular diseases: genetic causes and future therapeutics.

Authors:  Chih-Kang Chiang; Reiko Inagi
Journal:  Nat Rev Nephrol       Date:  2010-07-20       Impact factor: 28.314

Review 2.  Drug-induced thrombotic microangiopathy: incidence, prevention and management.

Authors:  R Pisoni; P Ruggenenti; G Remuzzi
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

3.  Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome.

Authors:  Jessica Caprioli; Marina Noris; Simona Brioschi; Gaia Pianetti; Federica Castelletti; Paola Bettinaglio; Caterina Mele; Elena Bresin; Linda Cassis; Sara Gamba; Francesca Porrati; Sara Bucchioni; Giuseppe Monteferrante; Celia J Fang; M K Liszewski; David Kavanagh; John P Atkinson; Giuseppe Remuzzi
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

Review 4.  Pathogenesis of the hemolytic uremic syndromes: current concepts.

Authors:  B S Kaplan; V V Vedaranayanan
Journal:  Indian J Pediatr       Date:  1988 Jul-Aug       Impact factor: 1.967

5.  Recurrent haemolytic-uraemic syndrome with hypocomplementaemia: a case report.

Authors:  R Bogdanović; A Cvorić; V Nikolić; M Sindjić
Journal:  Pediatr Nephrol       Date:  1988-04       Impact factor: 3.714

6.  Racial incidence of hemolytic-uremic syndrome.

Authors:  K J Sheth; J C Gill; P L Havens; H E Leichter
Journal:  Pediatr Nephrol       Date:  1995-06       Impact factor: 3.714

7.  Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome.

Authors:  Elena Goicoechea de Jorge; Claire L Harris; Jorge Esparza-Gordillo; Luis Carreras; Elena Aller Arranz; Cynthia Abarrategui Garrido; Margarita López-Trascasa; Pilar Sánchez-Corral; B Paul Morgan; Santiago Rodríguez de Córdoba
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-20       Impact factor: 11.205

Review 8.  Recent advances in understanding the pathogenesis of the hemolytic uremic syndromes.

Authors:  B S Kaplan; T G Cleary; T G Obrig
Journal:  Pediatr Nephrol       Date:  1990-05       Impact factor: 3.714

9.  Recurrent haemolytic uraemic syndrome and acquired hypomorphic variant of the third component of complement.

Authors:  A M Roodhooft; R H McLean; E Elst; K J Van Acker
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

Review 10.  STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

Authors:  Marina Noris; Federica Mescia; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-09-18       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.